Galvanize Therapeutics, a Redwood City, California, maker of pulsed electric field (PEF) ablation devices, said on 16 November 2026 that it had closed a $130m Series D round led by HealthQuest Capital. The company said the round was oversubscribed.
Olympus Innovation Ventures and Braidwell invested for the first time. Existing investors Sofinnova Partners, Norwest, Elevage Medical Technologies, Ally Bridge Group, Perceptive Advisors, Janus Henderson Investors, Longaeva Partners, Fidelity Management & Research Company and T. Rowe Price Associates also took part. Garheng Kong, founder and managing partner of HealthQuest, will join the board.
The company did not disclose a valuation. MedTech Dive noted that Galvanize did not give revenue figures. The round came about 14 months after a $100m Series C.
“This investment positions us to accelerate our growth and pursue our broader vision of expanding the impact of PEF across oncology and chronic disease.”Doug Godshall, Chairman and Chief Executive Officer, Galvanize Therapeutics
What Galvanize does
Pulsed electric field ablation uses short bursts of high-voltage energy to kill cells without heating tissue. According to MedTech Dive, the approach may cause less damage to healthy tissue than other ablation methods because it leaves the surrounding structure of the tissue in place.
The company's main product is the Aliya PEF System, which has 510(k) clearance from the US Food and Drug Administration for surgical ablation of soft tissue. It is sold only in the US. Galvanize said the FDA had cleared a next-generation Aliya EX generator during the past year and that it had launched the device commercially. MedTech Dive reported that the new generator can create ablation zones about 20mm across as well as the 10mm zones of the older device, which could widen the pool of patients who are eligible.
Galvanize said more than 4,000 procedures had been carried out with its technology, more than 300 patients had enrolled in its PROPEL registry, and more than 40 peer-reviewed papers had studied PEF. The company said early data suggested Aliya may help trigger an immune response, but that any patient benefit from this has not been established.
Its second product, RheOx, delivers PEF energy to the airways to reduce mucus-producing cells in people with chronic bronchitis. It remains an investigational device in the US; MedTech Dive reported that it launched in Europe in 2022.
What the money is for
Galvanize said the money would pay for wider commercial sales of Aliya, more clinical studies, development of RheOx and work on next-generation PEF products and platforms.
Chairman and chief executive Doug Godshall described the round as an important turning point for the company and said it had built a base with Aliya through physician adoption, sales and clinical data. Kong said HealthQuest had tracked the company for years and saw potential for its platform in interventional oncology and pulmonology. HealthQuest is a growth investor in commercial-stage healthcare companies with about $2bn in committed capital.
The funding so far
Galvanize was created by Apple Tree Partners, which incubated it alongside Gala Therapeutics and Galaxy Medical before the three merged in 2022. At the time of that merger, in September 2022, the combined company announced a $100m Series B led by Fidelity Management & Research Company.
In September 2025 it raised a $100m Series C led by Sofinnova Partners, with Norwest, Elevage Medical Technologies and Ally Bridge Group among the participants. Godshall, chairman of the board since 2021, was named chief executive at the same time. The company has not stated its total funding.
Company website: galvanizetx.com
